DE HB62

Prohibits manufacturers from imposing excessive price increases on generic and off-patent prescription drugs sold to Delaware consumers, with limits of 15% annually or 40% over 3 years (adjusted for inflation), or increases exceeding $30 per 30-day supply.

Requires pharmacy benefit managers and state agencies to notify the manufacturer and Attorney General of violations, with manufacturers having 45 days to submit cost justification statements to the Attorney General.

Authorizes the Attorney General to seek court orders for price restoration, consumer restitution, civil penalties up to $10,000 per day per violation (with each transaction counted separately), and requires revenues from violations be remitted to the State for drug cost reduction efforts.

Prohibits manufacturers from withdrawing generic or off-patent drugs from Delaware distribution to avoid the law's restrictions, with penalties of $500,000 for violations and required 180-day notice to the Board of Pharmacy and Attorney General before any withdrawal.

Becomes effective January 1, 2022.